A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia

about

Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.(Immuno)proteasomes as therapeutic target in acute leukemia.

P2860

Q37689041-37F62DFC-87F3-43DE-9449-5B9F5F33D57B Q47131929-988B0745-2866-4EB2-96B1-6064AA5386C3

P2860

A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia

Item

http://www.wikidata.org/entity/Q36955757

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A phase I study of carfilzomib ...... d acute lymphoblastic leukemia

@en

type

Item

label

A phase I study of carfilzomib ...... d acute lymphoblastic leukemia

@en

prefLabel

A phase I study of carfilzomib ...... d acute lymphoblastic leukemia

@en

P1476

A phase I study of carfilzomib ...... d acute lymphoblastic leukemia

@en

P2093

Amanda Cashen

http://www.w3.org/2001/XMLSchema#string

Emily R Hawkins

http://www.w3.org/2001/XMLSchema#string

Geoffrey L Uy

http://www.w3.org/2001/XMLSchema#string

Iskra Pusic

http://www.w3.org/2001/XMLSchema#string

John F DiPersio

http://www.w3.org/2001/XMLSchema#string

Keith E Stockerl-Goldstein

http://www.w3.org/2001/XMLSchema#string

Lukas D Wartman

http://www.w3.org/2001/XMLSchema#string

Mark A Fiala

http://www.w3.org/2001/XMLSchema#string

Meagan A Jacoby

http://www.w3.org/2001/XMLSchema#string

Peter Westervelt

http://www.w3.org/2001/XMLSchema#string

P2860

Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4

Targeted treatments for multiple myeloma: specific role of carfilzomib

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy

Proteasome inhibitors in acute leukemia.

Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

P304

728-730

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2015.1076930

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26674111

http://www.w3.org/2001/XMLSchema#string

P932

4888765

http://www.w3.org/2001/XMLSchema#string

A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia

about

P2860

P2860

A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932